Back to News
Market Impact: 0.1
Tarsus Pharmaceuticals Q3 Net Loss Widens To $668 Mln On Acquisition Costs As XDEMVY Sales Grow
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Tarsus Pharmaceuticals reported financial results for the third quarter ended September 30, 2026, and provided updates on its commercial business and development pipeline. The article excerpt provides no financial figures or specific pipeline developments.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- Snap shares fall over 10% on third-quarter earnings miss
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales